Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

Market Analysis and Insights: Global Nonalcoholic Steatohepatitis (NASH) Market
The global Nonalcoholic Steatohepatitis (NASH) market size is projected to reach US$ 46230 million by 2027, from US$ 3064.2 million in 2020, at a CAGR of 46.7% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nonalcoholic Steatohepatitis (NASH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nonalcoholic Steatohepatitis (NASH) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nonalcoholic Steatohepatitis (NASH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nonalcoholic Steatohepatitis (NASH) market.

Global Nonalcoholic Steatohepatitis (NASH) Scope and Market Size
Nonalcoholic Steatohepatitis (NASH) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Steatohepatitis (NASH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Obeticholic acid（OCA）
Selonsertib

Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead